Pfizer-BioNTech begin global study of lead COVID-19 vaccine candidate
The study is expected to include about 120 sites globally and could include up to 30,000 participants. It will include regions heavily impacted by COVID-19.
Full Article
Pfizer-BioNTech begin global study of lead COVID-19 vaccine candidate
Jerusalem Post
0 shares
1 views
You might like
Related news coverage
Why Are We Ignoring The Coming Autism Avalanche? – OpEd
Eurasia Review
By Pennel Bird*
Back in the year 2000 at the dawn of the new millennium, as Y2K fears faded to thin transparencies in..
Advertisement
More coverage
Benefits Of Routine Childhood Vaccines Far Outweigh Risks Of Additional COVID-19 Transmission In Africa
Eurasia Review
The health benefits of maintaining routine childhood vaccination programmes in Africa during the COVID-19 pandemic far outweigh the..
-
FTSE 100 clinging on to gains as sterling rallies
Proactive Investors
-
FTSE 100 shrugs off latest episode in US-China muscle-flexing contest
Proactive Investors
-
NA Proactive news snapshot: Ipsidy, Avalon GloboCare, BioSig Technologies, Co-Diagnostics, Black Iron, Thunderbird Entertainment UPDATE …
Proactive Investors
-
NA Proactive news snapshot: Thunderbird Entertainment, District Metals, GlobeX Data, Champignon Brands, Ipsidy UPDATE …
Proactive Investors